Quality assurance in molecular genetic testing laboratories

被引:59
作者
McGovern, MM
Benach, MO
Wallenstein, S
Desnick, RJ
Keenlyside, R
机构
[1] Mt Sinai Sch Med, Dept Human Genet, New York, NY USA
[2] Mt Sinai Sch Med, Dept Pediat, New York, NY USA
[3] Mt Sinai Sch Med, Dept Biomath, New York, NY USA
[4] Ctr Dis Control & Prevent, Div Lab Syst, Publ Hlth Practice Program Off, Atlanta, GA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1999年 / 281卷 / 09期
关键词
D O I
10.1001/jama.281.9.835
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Specific regulation of laboratories performing molecular genetic tests may be needed to ensure standards and quality assurance (QA) and safeguard patient rights to informed consent and confidentiality. However, comprehensive analysis of current practices of such laboratories, important for assessing the need for regulation and its impact on access to testing, has not been conducted. Objective To collect and analyze data regarding availability of clinical molecular genetic testing, including personnel standards and laboratory practices, Design A mail survey in June 1997 of molecular genetic testing laboratory directors and assignment of a QA score based on responses to genetic testing process items. Setting Hospital-based, independent, and research-based molecular genetic testing laboratories in the United States. Participants Directors of molecular genetic testing laboratories (n = 245; response rate, 74.9%), Main Outcome Measure Laboratory process QA score, using the American College of Medical Genetics Laboratory Practice Committee standards. Results The 245 responding laboratories reported availability of testing for 94 disorders, Personnel qualifications varied, although all directors had doctoral degrees. The mean QA score was 90% (range, 44%-100%) with 36 laboratories (15%) scoring lower than 70%. Higher scores were associated with test menu size of more than 4 tests (P = .01), performance of more than 30 analyses annually (P = .01), director having a PhD vs MD degree (P = .002), director board certification (P = .03), independent (P < .001) and hospital (P = .01) laboratories vs research laboratory, participation in proficiency testing (P < .001), and Clinical Laboratory Improvement Amendment certification (P = .006). Seventy percent of laboratories provided access to genetic counseling, 69% had a confidentiality policy, and 45% required informed consent prior to testing. Conclusion The finding that a number of laboratories had QA scores that may reflect suboptimal laboratory practices suggests that both personnel qualification and laboratory practice standards are most in need of improvement to ensure quality in clinical molecular genetic testing laboratories.
引用
收藏
页码:835 / 840
页数:6
相关论文
共 18 条
  • [1] *AM COLL HUM GEN L, 1993, STAND GUID CLIN GEN
  • [2] [Anonymous], 1994, RADON RENTAL HOUSING
  • [3] [Anonymous], 1992, FED REG
  • [4] *CHILDR HOSP REG M, 1999, HELIX DIR
  • [5] FUKIMARA FK, 1990, NEW ENGL J MED, V322, P61
  • [6] Holtzman N. A., 1997, PROMOTING SAFE EFFEC
  • [7] GENETIC DISCRIMINATION AND HEALTH-INSURANCE - AN URGENT NEED FOR REFORM
    HUDSON, KL
    ROTHENBERG, KH
    ANDREWS, LB
    KAHN, MJE
    COLLINS, FS
    [J]. SCIENCE, 1995, 270 (5235) : 391 - 393
  • [8] Lessons from hereditary colorectal cancer
    Kinzler, KW
    Vogelstein, B
    [J]. CELL, 1996, 87 (02) : 159 - 170
  • [9] Pharmacogenetics of cancer therapy: Getting personal
    Krynetski, EY
    Evans, WE
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 63 (01) : 11 - 16
  • [10] Personalised drug therapy could be near
    Larkin, M
    [J]. LANCET, 1998, 351 (9120) : 1937 - 1937